Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661604 | 1.00 | MPO (0.37) | MPONR1H4TLR9TLR8TLR7 | |
| SCHEMBL659054 | 1.00 | MPO (0.37) | MPONR1H4TLR9TLR8TLR7 | |
| SCHEMBL661072 | 0.91 | KDM1A (0.39) | TLR9TLR8TLR7KDM1A | |
| SCHEMBL661599 | 0.91 | KDM1A (0.39) | TLR9TLR8TLR7KDM1A | |
| SCHEMBL661815 | 0.91 | KDM1A (0.39) | TLR9TLR8TLR7KDM1A | |
| SCHEMBL662047 | 0.90 | MPO (0.37) | MPONR1H4TLR9TLR8TLR7 | |
| SCHEMBL661436 | 0.90 | MPO (0.37) | MPONR1H4TLR9TLR8TLR7 | |
| SCHEMBL662417 | 0.90 | MPO (0.37) | MPONR1H4TLR9TLR8TLR7 | |
| SCHEMBL661842 | 0.90 | MPO (0.37) | MPONR1H4TLR9TLR8TLR7 | |
| SCHEMBL661308 | 0.90 | MPO (0.37) | MPONR1H4TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2523944-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | Mithridion, Inc. (US) | 2012-11-21 | — | — | EP | claimed |
| US-20120046273-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2012-02-23 | — | — | US | claimed |
| EP-2403340-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | Mithridion, Inc. (US) | 2012-01-11 | — | — | EP | claimed |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MAPLIGHT THERAPEUTICS, INC. | 2011-10-27 | — | — | US | claimed |
| WO-2011085406-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2011-07-14 | — | — | WO | claimed |
| WO-2010102218-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2010-09-10 | — | — | WO | claimed |
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MITHRIDION, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | NEUROSOLIS INC (US) | 2017-11-02 | — | — | US | disclosed |
| US-9738633-B2 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160340348-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MAPLIGHT THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9403806-B1 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160199356-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MAPLIGHT THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9174972-B2 | Cognition enhancing compounds and compositions, methods of making, and methods of treating | NEUROSOLIS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130274299-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MAPLIGHT THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| EP-2523944-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | Mithridion, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120046273-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| EP-2403340-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | Mithridion, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MAPLIGHT THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| WO-2011085406-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2010102218-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | MITHRIDION, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340348-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | MPO 2290/4885NR1H4 586/4885TLR9 2565/4885 |
| US-20120046273-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | CHRM3, CHRM4, CHRM5 | MPO 1878/4885NR1H4 236/4885TLR9 1174/4885 |
| US-20130274299-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | MPO 2290/4885NR1H4 586/4885TLR9 2565/4885 |
| US-20110263613-A1 | COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING | CHRM3, ACHE, CHRM4 | MPO 1068/4885NR1H4 498/4885TLR9 2872/4885 |
| US-20160199356-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | MPO 2290/4885NR1H4 586/4885TLR9 2565/4885 |
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | MPO 2290/4885NR1H4 586/4885TLR9 2565/4885 |
| US-20170313687-A1 | Compounds and Compositions for Cognition-Enhancement, Methods of Making, and Methods of Treating | CHRM3, ACHE, CHRM4 | MPO 1068/4885NR1H4 498/4885TLR9 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.